Wegovy for Dogs: Setting the Record Straight

The myth worth addressing: Wegovy is not a universal weight-loss tool for any species

The search query is understandable. GLP-1 medicines have been covered heavily in the press, and the idea that a drug reducing appetite in humans might do the same in pets follows a reasonable-sounding logic. The reality is more complicated. Wegovy is approved by the MHRA specifically for adult humans, within a defined set of clinical criteria, as part of a managed programme that includes dietary changes and increased activity. The NHS medicines page for semaglutide sets this out clearly: its authorised uses are human weight management and, separately, type 2 diabetes in adults.

Veterinary medicine operates under a completely separate regulatory framework in the UK. Products for animals must be authorised through the Veterinary Medicines Directorate, not the MHRA. No semaglutide product holds VMD authorisation for use in dogs. That means supplying Wegovy for a dog would not only be outside the drug's licence, it would be outside the entire regulatory structure that governs animal medicines.

There is also a practical safety point. Dosing, formulation, metabolism and tolerability can differ substantially between species. What settles a human's appetite gently may not translate to a safe or effective dose in a dog, and the side-effect profile observed in human trials tells us nothing reliable about canine risk. A vet is the only person qualified to assess and manage a dog's weight, and they have tools specifically developed for that purpose.

What the animal research on GLP-1 medicines actually shows

Scientific curiosity about GLP-1 receptors in animals is real, and some early research has looked at how these pathways behave in non-human subjects. That research happens in controlled laboratory settings, not through human pharmacy dispensing. It does not constitute a basis for using a human prescription medicine in a pet at home.

For context on where human evidence currently stands: in the STEP 1 trial, published in the New England Journal of Medicine, semaglutide 2.4mg produced an average weight reduction of around 15% over 68 weeks in adults with obesity. That evidence base was built on thousands of people, with rigorous safety monitoring, titrated dosing under clinical supervision, and careful inclusion criteria. There is no equivalent body of evidence for dogs, and if you are curious about what is actually known on that front, our semaglutide and dogs page explains what the research does and does not show, and why a human pharmacy cannot help in this area.

If you want to read about the science behind semaglutide in more depth, our semaglutide overview covers how the medicine works in humans, what the evidence shows, and who it is intended for. The nume blog also carries pieces on the broader GLP-1 landscape as it develops.

Where to get the right help, for your dog and for yourself

If your dog is carrying excess weight, the right starting point is your vet. Canine obesity is taken seriously by UK veterinary professionals, and practices have specific guidance and products available for animal patients. The British Veterinary Association and RCVS-registered vets can direct you to licensed options; this is not territory a human pharmacy should enter.

If, separately, weight is something you have been thinking about for yourself, that is a different conversation, and one worth having. Many people who arrive at this page are researching the medicine on behalf of a pet but are quietly curious about whether it might be relevant to them too. That is not unusual, and it is not a strange thing to wonder about. A good place to start is our Wegovy eligibility guide, which explains who the medicine is licensed for, what the assessment involves, and what to expect from the process. You can also browse the full treatment options available through nume (including both Wegovy and Mounjaro) to understand how they compare for human weight management.

Wegovy is a prescription-only medicine. That means a registered prescriber reviews your health information and makes an independent clinical decision before anything is dispensed. A question many people also ask at this stage is whether treatment needs to continue indefinitely, and our page on whether Wegovy is for life addresses that honestly, covering what the evidence suggests about long-term use and what stopping the medicine can mean. At nume, that review is carried out by a GPhC-registered Independent Prescriber on the same day you submit your consultation. Our clinical team takes that responsibility seriously. If you have questions before starting, our FAQs page covers the most common ones, or you can contact us directly.

If human weight management is something you would like to explore, start your free consultation and a prescriber will review your details the same day.